Studio triveneto sulla lamotrigina: Motivi di sospensione della terapia

Translated title of the contribution: Lamotrigine triveneto study: Reasons for discontinuance of therapy

P. P. Benetello, P. G. Garofalo, C. Boniver, P. De Marco, E. Marotti, R. Amerio, M. A. Bassetti, P. Bergonzi, P. Blamino, L. G. Bongiovanni, F. Bouquet, G. Cagnin, S. Calzolari, R. Cernetti, P. Costa, G. Cristofori, B. Cruciatti, F. Dal Pozzo, G. De Polo, P. G. DolsoG. L. Gigli, D. Idone, B. Lucci, R. Marinig, G. Masè, P. G. Miottello, V. Munerati, D. Orrico, F. Paladin, A. Panìco, G. Pauletto, P. Pianalto, F. Privato, M. Prugger, L. Rozza, F. Sanson, R. Schoenhuber, M. Serena, M. Toldo, A. Tonon, G. Tortorici, M. Zamagni

Research output: Contribution to journalArticlepeer-review


We have followed, at 3, 6, 12, 24 months after the onset of therapy, 584 patients with refractory Generalized and Partial Epilepsy, started on LTG as add-on. Drop-out accounted for 32% of the SGE patients, 23% of the CGE, 13% IGE, and 40% EP. Lack of efficacy and side effect accounted for 71% and 29% respectively of drop-out rate. Most frequent adverse events were skin rashes and psychological disturbances.

Translated title of the contributionLamotrigine triveneto study: Reasons for discontinuance of therapy
Original languageItalian
Pages (from-to)323-324
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number118
Publication statusPublished - Oct 2002

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Lamotrigine triveneto study: Reasons for discontinuance of therapy'. Together they form a unique fingerprint.

Cite this